Материал: MasterPass _ Pharmacology in 7 Days for Medical Students

Внимание! Если размещение файла нарушает Ваши авторские права, то обязательно сообщите нам

PHARMACOLOGY IN 7 DAYS FOR MEDICAL STUDENTS

Vasodilatation and platelet

 

aggregation inhibition

 

Vasoconstriction & stimulation

of platelet aggregation

 

 

 

 

 

 

 

 

Fever, flushing (vasodilatation),

pain & diuresis

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Prostacyclin

 

(PGI

 

2

(TxA

 

 

 

 

 

 

 

 

PGE

 

 

 

 

 

 

 

 

ThromboxaneA

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

)

 

 

 

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2

 

 

 

 

2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2

 

 

 

 

 

 

 

 

 

synthase

 

 

 

 

 

isomerase

 

macrophages)

 

 

 

 

 

 

 

 

 

endothelial

 

 

 

 

 

 

&

 

 

 

 

&

 

 

 

 

cells)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

uterus)

 

 

synthase

 

 

 

platelets)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2

 

 

 

 

α

 

 

 

 

 

 

 

 

 

Thromboxane

PGE

 

mast

cells

PGF

2

lungs

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(in

 

(in

 

 

 

 

 

 

 

 

 

 

 

Prostacyclin

 

 

 

 

 

 

 

 

 

 

 

(in

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(in

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

PGH

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

PGG

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

COX-1 & COX-2

 

 

 

 

 

 

 

NSAIDs &

COX-2 inhibitors

 

 

 

 

 

 

 

 

 

 

 

enzymes

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Arachidonic acid

 

 

 

 

 

 

 

 

 

 

 

 

Bronchoconstriction & abortion

metabolism)

 

 

acid

 

 

 

 

arachidonic

PGF

α

 

2

 

 

 

(cyclo-oxygenase pathway of

 

 

Figure 3.18 Prostaglandins synthesis and functions

84

MECHANISMS OF ACTION

Platelets bind to vascular subendothelial collagen cells via von

Willebrand factor. Platelets bind with each other via fibrinogen strands

GPIIb-IIIa

 

receptors on platelet

Platelet

membranes

 

 

Fibrinogen

Platelet

GPIb receptors on platelet membrane

 

von Willebrand factor

Subendothelial collagen cells

Figure 3.19 Mechanism of platelets adhesion and aggregation

receptors present on platelet cell membranes in turn causing activation of adenylyl cyclase → ↑ intracellular cAMP → platelet aggregation inhibition. cAMP is degraded by phosphodiesterase (PDE) enzyme into inactive AMP. Dipyridamole, another antiplatelet drug, inhibits PDE → ↑ intracellular cAMP → platelet aggregation inhibition.

Methotrexate

As a DMARD: It is a disease-modifying antirheumatic drug (DMARD). It acts by inhibiting lymphoid proliferation and thus reducing the number of immune cells available to participate in the inflammatory response.

Clopidogrel

ADP

 

ADP

 

Ticlopidine

 

 

receptor

Dipyridamole

Adenylyl cyclase

 

ATP

cAMP PDE

AMP

 

 

(inactive)

Platelet aggregation inhibition by a poorly understood mechanism

P

l

a

t

elet

Figure 3.20 ADP-dependent pathway of platelet activation

85

PHARMACOLOGY IN 7 DAYS FOR MEDICAL STUDENTS

As an anticancer drug: DNA synthetic pathway:

Methotrexate is a substrate for and inhibitor of dihydrofolate reductase. Inhibition of this enzyme blocks DNA synthesis at two points:

1It decreases the synthesis of purine and pyrimidine nucleotides.

2It decreases the synthesis of DNA from deoxynucleotides.

Cyclophosphamide

It is a prodrug that is transformed by hepatic cytochrome P450 enzymes to an alkylating agent. Just like other alkylating agents, cyclophosphamide is a cell cyclenonspecific (CCNS) drug. It damages DNA by alkylating nucleophilic groups on DNA bases (particularly the N-7 position of guanine). This leads to crosslinking of bases, abnormal base pairing and ultimate breakage of DNA strands. Cyclophosphamide is cytotoxic to proliferating lymphoid cells – both B and T lymphocytes (→ immunosuppression), although, effect on the former cells is greater.

Vincristine and vinblastine

Vinca alkaloids (vincristine and vinblastine) are cell cycle-specific agents that primarily act in the M phase of cancer cell cycle. They prevent the assembly of tubulin dimmers into microtubules. This in turn blocks the formation of mitotic spindles.

Doxorubicin and daunorubicin

These anthracyclines are cell cycle-nonspecific (CCNS) drugs. They intercalate between base pairs, inhibit topoisomerase II and generate free radicals. Free radicals in turn block the synthesis of RNA and DNA and cause scission of DNA strands.

Amphotericin B

It is a polyene antifungal agent. Polyene molecules are amphipathic, i.e. they are both hydrophilic and lipophilic. They bind to ergosterol (a sterol specifically found in the cell membranes of fungi) in turn causing the formation of artificial pores in fungal cell membranes. These pores allow leakage of intracellular ions and macromolecules eventually leading to cell death.

Nystatin

Just like amphotericin B, Nystatin is a polyene antifungal agent. Its mechanism of action is similar to that of amphotericin B.

Griseofulvin

It is taken up by sensitive dermatophytes by an energy-dependent mechanism. Once inside the cytoplasm, Griseofulvin interferes with microtubular function and inhibits synthesis and polymerisation of nucleic acids. The net result is death of dermatophytes.

Acyclovir

Acyclovir is a guanosine analogue. It is activated by a viral enzyme called thymidine kinase to form acyclovir triphosphate. The latter is incorporated into viral DNA, where it causes chain termination by inhibiting viral DNA polymerase.

Since phosphorylation of acyclovir is necessary for its antiviral effect, viral strains

86

MECHANISMS OF ACTION

that lack thymidine kinase are resistant to acyclovir. Also, a change in viral DNA polymerase so that it is no longer inhibited by acyclovir triphosphate can cause viral resistance to acyclovir.

Metoclopramide

In the enteric nervous system (ENS), metoclopramide increases upper GI motility by:

1Acting as an acetylcholine facilitator.

2Acting as dopamine receptor antagonists.

The net effect is an increase in upper GI motility with resultant alleviation of vomiting.

Antiarrhythmic drugs

Table 3.3

Class Example

Mnemonic: MBA college Mechanism

Ia

Disopyramide

Membrane stabilisers

 

 

(Na+ channel blockage →

 

 

membrane stabilisation)

Ib

Lidocaine

Membrane stabilisers

 

 

(Na+ channel blockage →

 

 

membrane stabilisation)

Ic

Flecainide

Membrane stabilisers

 

 

(Na+ channel blockage →

 

 

membrane stabilisation)

II

Propranolol

Beta blockers

III

Amiodarone,

Action potential widening

 

sotalol

agents (K+ channel blockage

 

 

→ widening of AP)

Na+ channel blockers (prolong the AP; intermediate dissociation)

Na+ channel blockers (shorten the AP; fast dissociation)

Na+ channel blockers (no effect on AP duration; slow dissociation)

β-Adrenoceptor blockers

K+ channel blockers

IV

Verapamil

Calcium channel blockers

Ca++ channel blockers

 

 

 

 

 

Class

Example

PR interval

QRS duration

QT interval

 

 

 

 

 

 

Ia

Disopyramide

↓ or ↑*

↑↑

 

↑↑

Ib

Lidocaine

Ð

Ð

 

Ð

Ic

Flecainide

↑ (slightly)

↑↑

 

Ð

II

Propranolol

↑↑

Ð

 

Ð

III

Amiodarone,

↑↑

 

↑↑↑↑

 

sotalol

Ð

 

↑↑↑

IV

Verapamil

↑↑

Ð

 

Ð

Misc

Adenosine

Ð

 

Ð

*PR interval may ↓ d/t antimuscarinic action; it may ↑ d/t Na+ channel blocking action

87

PHARMACOLOGY IN 7 DAYS FOR MEDICAL STUDENTS

Calcium channel blockers

These drugs block voltage-gated ‘L-type’ Ca++ channels found in cardiac and other smooth muscle tissues → ↓ Ca++ influx → ↓ cytoplasmic Ca++ concentration → ↓ muscle contractility (vasodilatation, and to a lesser extent dilatation of bronchial, gut and uterine smooth muscles). All Ca++ channels blockers reduce BP. Effect on heart rate is, however, variable. Diltiazem and verapamil block Ca++-dependent AV nodal conduction → slowing of heart rate. Nifedipine and other dihydropyridines Ca++ channel blockers primarily affect the peripheral blood vessels → peripheral vasodilatation → ↓ BP → reflex tachycardia.

Note: Since ‘L-type’ Ca++ channels are not found at NM junctions and in endocrine tissues, Ca++ channel blockers do not affect the release of neurotransmitters or hormones.

K+ channel openers (minoxidil, nicorandil)

K+ channel openers (minoxidil, nicorandil), as the name suggest, open K+ channels present in the cell membranes of myocytes causing K+ efflux. The resultant hyperpolarisation makes membrane depolarisation difficult to achieve by normal excitatory stimuli. In the absence of depolarisation, voltage gated Ca++ channels responsible for Ca++ influx do not open. The resultant fall in intracellular Ca++ leads to arterial smooth muscle relaxation.

Angiotensin-converting enzyme inhibitors (ACEIs)

Physiologic role of angiotensin-converting enzyme (ACE): ACE (also known as kininase-II and peptidyl dipeptidase) is responsible for the conversion of:

1Angiotensin-I to angiotensin-II. The latter has three important effects: a It is a potent vasoconstrictor (→ ↑ peripheral vascular resistance).

b It acts on angiotensin AT1 receptors on the adrenal cortex and causes the release of aldosterone, which in turn causes Na+ and water reabsorption in exchange of K+ and H+ from the distal convoluting tubules of the nephron.

 

Ca++

 

 

 

 

Ca++

 

 

 

 

Ca++-Calmodulin complex

 

 

 

 

Myosin light chain kinase enzyme

 

 

 

 

 

 

Myosin phosphorylation

 

 

 

 

 

 

Actin-Myosin crossbridges

 

 

 

 

 

Myocyte

Contraction

 

 

Figure 3.21 Mechanism of vascular smooth muscle contraction

88